Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
VYNE Therapeutics Inc. (MNLO)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Cost of goods sold | 59.1% | 10.0% | 6.6% | 4.1% | 1.2% | 0.0% | 0.0% | |
| Gross profit | 40.9% | 90.0% | 93.4% | 95.9% | 98.8% | 100.0% | 100.0% | |
| Selling, general and administrative | 3435.4% | 2180.3% | 426.5% | 10183.7% | 389.8% | | | |
| Research and development | 3854.3% | 2099.1% | 207.4% | 11558.0% | 1793.4% | 633.1% | 1669.9% | |
| General and administrative | | | | | | 112.8% | 556.5% | |
| EBITDA | -7233.8% | -4177.8% | -952.5% | -21566.8% | -2075.6% | -645.7% | -2125.8% | |
| Depreciation | 15.1% | 11.7% | 1.6% | 79.0% | 8.9% | 0.2% | 0.6% | |
| EBIT | -7248.8% | -4189.5% | -954.1% | -21645.8% | -2084.5% | -645.9% | -2126.4% | |
| Pre-tax income | -7113.6% | -4796.6% | 1218.6% | 21524.6% | 2057.1% | -634.6% | -2087.2% | |
| Income taxes | 2.7% | -48.1% | 1.2% | 39.7% | -5.9% | 0.0% | 0.0% | |
| Net income | -4863.7% | -7876.4% | 1217.4% | 21484.9% | 2062.9% | -634.6% | -2087.2% | |
|